

In the claims:

1-7 (canceled).

8. (previously presented) The stent of claim 46 comprising:
a radially self-expanding tubular shaped member having first and second ends; a
walled surface disposed between said first and second ends;
said walled surface comprising a plurality of substantially parallel pairs of
monofilaments; said substantially parallel pairs of monofilaments woven in a helical
shape such that substantially one-half of said substantially parallel pairs of
monofilaments are wound clockwise in the longitudinal direction and one-half of said
substantially parallel pairs of monofilaments are wound counterclockwise in the
longitudinal direction such that an alternating, over-under plait of said substantially
parallel pairs of monofilaments results; said monofilaments comprising a blend of at least
two bioresorbable, bio-compatible homopolymers.

9. (previously presented) The stent of claim 8, comprising approximately twenty-
four substantially parallel pairs of monofilaments.

10. (previously presented) The stent of claim 8, wherein said bioresorbable, bio-
compatible homopolymers are selected from the group consisting of poly-L-lactide, poly-
D-L-lactide and poly-ε-caprolactone.

11. (previously presented) The stent of claim 8, wherein said polymer blend
possesses a tensile strength in the range of approximately 40,000 psi to 120,000 psi.

12. (previously presented) The stent of claim 8, wherein said polymer blend
possesses a tensile modulus in the range of approximately 400,000 psi and 2,000,000 psi.

13. (original) The bioresorbable stent of claim 8, wherein said stent has a compressed first diameter of between approximately 6 mm to 10 mm and a second non-compressed diameter of between approximately 12 mm and 18 mm.

14. (original) The bioresorbable stent of claim 8 wherein said woven monofilaments have a crossing angle of between approximately 100 degrees to 150 degrees in the non-compressed resting state.

15-45 (canceled).

46. (currently amended) A bioresorbable, self-expanding stent comprising a tubular-shaped bioresorbable member having first and second ends, said bioresorbable member comprising a blend of at least two bioresorbable, bio-compatible homopolymers, the stent having a non-compressed diameter of between approximately 12 millimeters and 18 millimeters.

47. (previously presented) The stent of claim 46 comprising:
a tubular-shaped member having first and second ends;
a walled surface disposed between said first and second ends;
said walled surface comprising a helical shape of woven monofilaments comprising a blend of at least two bioresorbable, bio-compatible homopolymers.

48. (previously presented) The stent of claim 47, wherein said blend of bioresorbable, bio-compatible polymers is selected from the group consisting of poly-L-lactide, poly-D-L-lactide and poly- ϵ -caprolactone.

49. (previously presented) The stent of claim 47, wherein said walled structure has approximately 30 monofilaments.

50. (previously presented) The stent of claim 47, wherein said polymer blend possesses a tensile strength in the range of approximately 40,000 psi to 120,000 psi.

51. (previously presented) The stent of claim 47, wherein said polymer blend possesses a tensile modulus in the range of approximately 400,000 psi and 2,000,000 psi.

52. (previously presented) The stent of claim 47, wherein said stent has a compressed first diameter of between approximately 6 mm to 10 mm and a second non-compressed diameter of between approximately 12 mm and 18 mm.

53. (previously presented) The stent of claim 47, wherein said woven monofilaments have a crossing angle of between approximately 100 degrees to 150 degrees in the non-compressed resting state.

54. (previously presented) The stent of claim 46, wherein the stent comprises a substantially tubular shaped device;

said tubular shape device having a first and second ends;
a walled structure disposed between said first and second ends;
said walled structure having fenestrations therein, said walled surface comprising a blend of at least two bioresorbable, bio-compatible homopolymers.

55. (previously presented) The stent of claim 54, wherein the homopolymers are selected from the group consisting of poly-L-lactide, poly-D,L-lactide and poly- ϵ -caprolactone.

56. (previously presented) The stent of claim 54, wherein said polymer blend possesses a tensile strength in the range of approximately 8,000 psi to 12,000 psi.

57. (previously presented) The stent of claim 54, wherein said polymer blend possesses a tensile modulus in the range of approximately 400,000 psi and 800,000 psi.

58. (previously presented) The stent of claim 54, wherein said stent has a compressed first diameter of between approximately 6 mm to 10 mm and a second non-compressed diameter of between approximately 12 mm and 18 mm.

59. (previously presented) The stent of claim 46, wherein the stent is a urethral stent.

60. (previously presented) The stent of claim 46, wherein the stent comprises a blend of homopolymers in a ratio of between approximately 50:50 to 70:30.

[Please add claims 61-65.]

61. (new) A bioresorbable, self-expanding stent comprising, wherein the stent comprises a substantially tubular shaped device; said tubular shape device having a first and second ends; a walled structure disposed between said first and second ends; said walled structure having fenestrations therein, said walled surface comprising a blend of at least two bioresorbable, bio-compatible homopolymers.

62. (new) The stent of claim 61 wherein the homopolymers are selected from the group consisting of poly-L-lactide, poly-D,L-lactide and poly- ϵ -caprolactone.

63. (new) The stent of claim 61 wherein said stent has a compressed first diameter of between approximately 6 millimeter to 10 millimeter and a second non-compressed diameter of between approximately 12 millimeter and 18 millimeter.

[Support for added claims 61 through 63 can be found in the specification as originally filed, e.g., at original claims 15, 16, and 19.]

64. (new) The stent of claim 61 wherein the stent is a urethral stent.

Support for added claim 64 can be found in the specification as originally filed, e.g., at page 5, lines 7-10. 

D,
65. (new) The stent of claim 61 wherein the stent comprises a blend of homopolymers in a ratio of between approximately 50:50 to 70:30.

Support for added claim 65 can be found in the specification as originally filed, e.g., at claim 36, now canceled. 
